If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML) and how it unfolds over time. Decades of pharmacovigilance have established that PML risk increases with longer treatment duration, particularly beyond two years. This page provides a clear, evidence-based overview of the PML timeline, risk factors, and what monitoring involves.
Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The following narrative integrates clinical presentation, pharmacological mechanisms, and risk considerations, including settlement-related factors for affected patients. Progressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system that typically occurs in immunocompromised individuals. Clinical presentation often includes progressive neurological deficits such as weakness, sensory loss, visual disturbances, cognitive decline, and ataxia. Diagnosis relies on MRI findings showing multifocal white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri functions by binding to alpha-4 integrins on leukocytes, inhibiting their migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system but also impairs immune surveillance, particularly against JC virus. The mechanistic pathway linking Tysabri to PML involves reduced trafficking of virus-specific T cells into the brain, allowing JC virus reactivation and uncontrolled replication in oligodendrocytes. This leads to lytic infection and progressive demyelination (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk for developing PML. These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both had received Tysabri in addition to interferon beta-1a), and one after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML is a central issue. The prescribing information includes a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold dosing immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Despite these warnings, questions may arise about whether patients and healthcare providers were adequately informed of the magnitude and nature of the risk, particularly in the context of combination therapy or prolonged use. Settlement-related considerations for affected patients involve the timeline between Tysabri exposure and documented harm. PML typically develops after several months to years of treatment, with risk increasing beyond two years of therapy. In clinical trials, cases were observed after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who develop PML may face substantial medical costs, long-term disability, and reduced quality of life. Legal claims often focus on whether the manufacturer provided sufficient warnings about PML risk and whether patients were adequately monitored. Settlement amounts may reflect the severity of injury, medical expenses, lost income, and pain and suffering. In summary, Tysabri-associated PML is a serious adverse event with well-characterized risk factors and clinical presentation. The prescribing information includes explicit warnings and monitoring requirements, but affected patients may still pursue legal recourse if they believe warnings were inadequate or if harm occurred despite appropriate use. Understanding the mechanistic link, risk factors, and timeline is essential for both clinical management and legal evaluation.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and Crohn's disease. It works by binding to alpha-4 integrins on leukocytes, inhibiting their migration across the blood-brain barrier, which reduces inflammatory activity in the central nervous system but also impairs immune surveillance against JC virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
PML is a severe opportunistic brain infection caused by the JC virus. It leads to progressive demyelination of the central nervous system, typically in immunocompromised individuals. Symptoms include weakness, sensory loss, visual disturbances, cognitive decline, and ataxia. Diagnosis is confirmed by MRI and detection of JC virus DNA in cerebrospinal fluid. PML usually results in death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three established risk factors are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Patients who developed PML after Tysabri use may pursue legal claims if they believe the manufacturer provided inadequate warnings about PML risk or if monitoring was insufficient. Settlement amounts may reflect the severity of injury, medical expenses, lost income, and pain and suffering. It is important to consult with a legal professional experienced in pharmaceutical litigation.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.